201 related articles for article (PubMed ID: 32852239)
1. Prognostic value of MRD monitoring based on
Arunachalam AK; Janet NB; Korula A; Lakshmi KM; Kulkarni UP; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Leuk Lymphoma; 2020 Dec; 61(14):3468-3475. PubMed ID: 32852239
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
Arunachalam AK; Selvarajan S; Mani T; Janet NB; Maddali M; Lionel SA; Kulkarni U; Korula A; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
Cytometry B Clin Cytom; 2023 Nov; 104(6):440-452. PubMed ID: 37555390
[TBL] [Abstract][Full Text] [Related]
5. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; Dongen JJMV; Ottmann OG
Leukemia; 2019 Aug; 33(8):1910-1922. PubMed ID: 30858550
[TBL] [Abstract][Full Text] [Related]
6. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract][Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
9. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Papayannidis C; Candoni A; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci C; Rambaldi A; Guarini A; Bassan R; Foà R
Haematologica; 2021 Jun; 106(6):1559-1568. PubMed ID: 32467145
[TBL] [Abstract][Full Text] [Related]
10. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J; Hovorkova L; Krotka J; Koehrmann A; Bardini M; Winkowska L; Fronkova E; Alten J; Koehler R; Eckert C; Brizzolara L; Trkova M; Stuchly J; Zimmermann M; De Lorenzo P; Valsecchi MG; Conter V; Stary J; Schrappe M; Biondi A; Trka J; Zaliova M; Cazzaniga G; Cario G
Leukemia; 2022 Dec; 36(12):2793-2801. PubMed ID: 35933523
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
Gupta SK; Bakhshi S; Chopra A; Kamal VK
Leuk Lymphoma; 2018 Aug; 59(8):1899-1904. PubMed ID: 29199525
[TBL] [Abstract][Full Text] [Related]
13. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
14. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
16. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
[TBL] [Abstract][Full Text] [Related]
17. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
18. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.
Tang GS; Wu J; Liu M; Chen H; Gong SG; Yang JM; Hu XX; Wang JM
Am J Transl Res; 2015; 7(3):632-9. PubMed ID: 26045902
[TBL] [Abstract][Full Text] [Related]
20. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38485650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
